Literature DB >> 16944931

Quantitative profiling of drug-associated proteomic alterations by combined 2-nitrobenzenesulfenyl chloride (NBS) isotope labeling and 2DE/MS identification.

Keli Ou1, Djohan Kesuma, Kumaresan Ganesan, Kun Yu, Sou Yen Soon, Suet Ying Lee, Xin Pei Goh, Michelle Hooi, Wei Chen, Hiroyuki Jikuya, Tetsuo Ichikawa, Hiroki Kuyama, Ei-ichi Matsuo, Osamu Nishimura, Patrick Tan.   

Abstract

The identification of drug-responsive biomarkers in complex protein mixtures is an important goal of quantitative proteomics. Here, we describe a novel approach for identifying such drug-induced protein alterations, which combines 2-nitrobenzenesulfenyl chloride (NBS) tryptophan labeling with two-dimensional gel electrophoresis (2DE)/mass spectrometry (MS). Lysates from drug-treated and control samples are labeled with light or heavy NBS moiety and separated on a common 2DE gel, and protein alterations are identified by MS through the differential intensity of paired NBS peptide peaks. Using NBS/2DE/MS, we profiled the proteomic alterations induced by tamoxifen (TAM) in the estrogen receptor (ER) positive MCF-7 breast cancer cell line. Of 88 protein spots that significantly changed upon TAM treatment, 44 spots representing 23 distinct protein species were successfully identified with NBS-paired peptides. Of these 23 TAM-altered proteins, 16 (70%) have not been previously associated with TAM or ER activity. We found the NBS labeling procedure to be both technically and biologically reproducible, and the NBS/2DE/MS alterations exhibited good concordance with conventional 2DE differential protein quantitation, with discrepancies largely due to the comigration of distinct proteins in the regular 2DE gels. To validate the NBS/2DE/MS results, we used immunoblotting to confirm GRP78, CK19, and PA2G4 as bona fide TAM-regulated proteins. Furthermore, we demonstrate that PA2G4 expression can serve as a novel prognostic factor for disease-free survival in two independent breast cancer patient cohorts. To our knowledge, this is the first report describing the proteomic changes in breast cancer cells induced by TAM, the most commonly used selective estrogen receptor modulator (SERM). Our results indicate that NBS/2DE/MS may represent a more reliable approach for cellular protein quantitation than conventional 2DE approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944931     DOI: 10.1021/pr060115n

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  11 in total

Review 1.  The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.

Authors:  Anne W Hamburger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-19       Impact factor: 2.673

2.  Identification of a hormone-regulated dynamic nuclear actin network associated with estrogen receptor alpha in human breast cancer cell nuclei.

Authors:  Concetta Ambrosino; Roberta Tarallo; Angela Bamundo; Danila Cuomo; Gianluigi Franci; Giovanni Nassa; Ornella Paris; Maria Ravo; Alfonso Giovane; Nicola Zambrano; Tatiana Lepikhova; Olli A Jänne; Marc Baumann; Tuula A Nyman; Luigi Cicatiello; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2010-03-22       Impact factor: 5.911

Review 3.  A structural view of PA2G4 isoforms with opposing functions in cancer.

Authors:  Brendan W Stevenson; Michael A Gorman; Jessica Koach; Belamy B Cheung; Glenn M Marshall; Michael W Parker; Jessica K Holien
Journal:  J Biol Chem       Date:  2020-09-20       Impact factor: 5.157

4.  Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor.

Authors:  Zhixue Liu; Sang-Muk Oh; Masashi Okada; Xia Liu; Dongmei Cheng; Junmin Peng; Daniel J Brat; Shi-yong Sun; Wei Zhou; Wei Gu; Keqiang Ye
Journal:  Mol Biol Cell       Date:  2008-11-26       Impact factor: 4.138

5.  Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells.

Authors:  Rosita Russo; Nunzia Matrone; Valentina Belli; Davide Ciardiello; Mariangela Valletta; Sabrina Esposito; Paolo Vincenzo Pedone; Fortunato Ciardiello; Teresa Troiani; Angela Chambery
Journal:  Cancers (Basel)       Date:  2019-09-25       Impact factor: 6.639

Review 6.  The roles of multifunctional protein ErbB3 binding protein 1 (EBP1) isoforms from development to disease.

Authors:  Inwoo Hwang; Hyo Rim Ko; Jee-Yin Ahn
Journal:  Exp Mol Med       Date:  2020-07-27       Impact factor: 8.718

7.  Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.

Authors:  Arzu Umar; Hyuk Kang; Annemieke M Timmermans; Maxime P Look; Marion E Meijer-van Gelder; Michael A den Bakker; Navdeep Jaitly; John W M Martens; Theo M Luider; John A Foekens; Ljiljana Pasa-Tolić
Journal:  Mol Cell Proteomics       Date:  2009-03-27       Impact factor: 5.911

8.  Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility.

Authors:  Antoine M Snijders; Francesco Marchetti; Sandhya Bhatnagar; Nadire Duru; Ju Han; Zhi Hu; Jian-Hua Mao; Joe W Gray; Andrew J Wyrobek
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

9.  Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.

Authors:  A Ghosh; S Awasthi; J R Peterson; A W Hamburger
Journal:  Br J Cancer       Date:  2013-01-29       Impact factor: 7.640

10.  P42 Ebp1 functions as a tumor suppressor in non-small cell lung cancer.

Authors:  Hyo Rim Ko; Truong Lx Nguyen; Chung Kwon Kim; Youngbin Park; Kyung-Hoon Lee; Jee-Yin Ahn
Journal:  BMB Rep       Date:  2015-03       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.